🧾 What This Document Is

This is TherapeuticsMD's annual report (Form 10-K) for the year ended December 31, 2025. It's a mandatory, detailed filing with the SEC that gives a full picture of the company's business, financial condition, risks, and performance for the year. Think of it as the company's official, comprehensive report card.

🏢 What The Company Does

👉 In simple terms, TherapeuticsMD is now a "pharmaceutical royalty collector." It no longer makes or sells drugs itself. Instead, it owns the rights to a portfolio of women's health products and licenses them to other companies (like Mayne Pharma) that handle all the manufacturing, sales, and marketing. TherapeuticsMD's main job is to collect royalty checks based on the sales of those products.

Its key licensed products are:

IMVEXXY & BIJUVA: FDA-approved hormone therapies for menopause symptoms.
ANNOVERA: A one-year, reusable prescription contraceptive ring.
Prenatal Vitamins: Prescription vitamin lines.

This model shifted completely on December 30, 2022, when it handed over all commercial operations to its licensees.

💰 Financial Highlights

The numbers tell a story of a company in transition, relying on royalty streams while managing costs.

Revenue: Came entirely from license royalties. The company has three main licensees, making revenue concentration a key risk.
Profitability: The company is not currently profitable. It reported a net loss of $569,000 for 2025 and $2.2 million for 2024.
Cash & Going Concern: As of December 31, 2025, it had $7.5 million in cash. Crucially, its auditors have expressed "substantial doubt" about its ability to continue as a going concern for the next year. This is a major red flag for investors.
Equity: Stockholders' equity stood at $26.9 million as of year-end.

🚀 Key Moves & Strategic Shift

The defining move was the "Mayne Transaction" in late 2022. TherapeuticsMD essentially turned itself inside out:

Licensed/Assigned all its key products (IMVEXXY, BIJUVA, ANNOVERA, prenatal vitamins) to Mayne Pharma.
Hired a minimal team; it now has only one employee, CEO Marlan D. Walker.
Stopped all manufacturing, R&D, and commercial sales activities.
The goal was to become a lean, asset-light company collecting royalties.

⚖️ Big Picture: Strengths & Risks

👍 Strengths:

Focused Portfolio: Owns rights to FDA-approved, branded products in a dedicated niche (women's health).
Simplified Model: No more heavy costs of R&D, manufacturing, or large sales forces.
Existing Products: Revenue comes from products already on the market.

⚠️ Overwhelming Risks:

Going Concern: The auditors' warning is the #1 risk. The company may run out of money.
Total Dependence on Licensees: Its fate is tied to Mayne Pharma's (and others') ability to successfully sell the products. If sales falter, TherapeuticsMD's royalties drop.
Disputes with Mayne Pharma: Ongoing lawsuits over royalty calculations could lead to "significant damages" and hurt cash flow.
Legal Threats: The patents protecting its products (especially IMVEXXY) are being challenged by generic drug companies (like Teva and Sun Pharma). A loss in court could slash royalty rates.
Key Person Risk: The entire company relies on its sole employee, Marlan Walker.
Operational Wind-Down: The costs of shutting down its old business are ongoing.

🔮 What's Next?

The path forward is narrow and fraught with challenge:

Collect Royalties & Resolve Disputes: Its survival depends on receiving royalties from Mayne Pharma and settling the ongoing lawsuits without severe financial penalties.
Defend Intellectual Property: It must rely on its licensees (Mayne) to fight patent challenges in court to delay generic competition.
Manage a Minimal Operation: Keep costs ultra-low with just one employee and consultants.
Seek New Financing: Given the going concern status, it will likely need to raise more money, which could dilute existing shareholders.

🧠 The Analogy

TherapeuticsMD is like a landlord who owns a few rental properties but has handed over all management, repairs, and tenant-finding to a property management company (Mayne Pharma). The landlord just collects a monthly check. The problem is, the management company is arguing over the fees, the properties' value is threatened by new zoning laws (generic competition), and the landlord's own savings account is almost empty. If the checks stop coming or get smaller, the landlord could lose everything.

📇 Key Contacts & People

Marlan D. Walker: Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer, Secretary, Treasurer, and sole employee.
Company Address: 951 Yamato Road, Suite 220, Boca Raton, Florida 33431
Phone Number: (561) 961-1900
Independent Auditor: Carr, Riggs & Ingram, L.L.C.

🧩 Final Takeaway

TherapeuticsMD has transformed into a royalty company facing existential risk. While it owns rights to real, marketed products, its future is precarious due to severe liquidity concerns, costly legal battles with its main partner, and patent challenges. The "going concern" warning means investors must be extremely cautious, as the company's survival is not guaranteed.

TherapeuticsMD, Inc. — 10-K Filing